Earl Martin Douglas - 21 Aug 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: SVP, General Counsel
Issuer ticker: ALLO
Reported as of: 21 Aug 2026
Net transaction value: -$62,958
SEC form: 4
Accepted by SEC: 25 Aug 2026, 16:43:22 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/Earl Douglas

Key filing fact

Earl Martin Douglas filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 25 Aug 2026.

Key facts

This page summarizes Earl Martin Douglas's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Aug 2026, 16:43.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: -$62,958.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001362155 Primary reporting owner

Douglas Earl Martin

Relationship: SVP, General Counsel
Address: 210 EAST GRAND AVE, SOUTH SAN FRANCISCO
Signature: /s/Earl Douglas
Signature date: 25 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLO transaction

Common Stock

Sale

Transaction value: $62,958
Shares: -29,697
Change %: -5.7%
Price: $2.12
Shares after: 488,267
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F2

Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023.

Footnote F3

Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.